NCT02295787撤回4 期
Intranasal Ketamine for Late-Life Depression and Suicidal Ideation
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 主要终点
- Hamilton Depression Rating Scale (HDRS)
研究概览
简要总结
The investigators of this study plan to investigate the feasibility and efficacy of repeated doses of intranasal ketamine in severely depressed patients who are at least 65 years of age and experiencing suicidal ideation. The results of the study could lead to development of new strategies for treating depression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •be ≥65 years old, 2) provide written informed consent, 3) meet criteria for a primary psychiatric diagnosis of major depressive disorder according to the Structured Clinical Interview for DSM-IV (SCID) and have a HDRS28 total score ≥20; depression may have started at any time point in their life, and certain co-morbid diagnoses (e.g., anxiety disorders) will be allowed insofar as they are not the primary psychiatric diagnosis, 4) have a history of ≥2 failed medication trials during the current episode (per the Massachusetts General Hospital Antidepressant Treatment History Questionnaire; MGH ATRQ), 5) endorse suicidal ideation for more than 2 months, per the Columbia Suicide Severity Rating Scale (C-SSRS) and have a HDRS28 suicide item score ≥1 (thoughts that life isn't worth living), 6) be on a stable antidepressant regimen for ≥14 days prior to Study Phase II, 7) maintain a treating psychiatrist who is in agreement with study participation, and 8) have a reliable chaperone accompany them home following the completion of the intranasal administration.
排除标准
- •Patients will be excluded if any of the following criteria are met: 1) Delirium or dementia diagnosis, 2) unstable medical illness, 3) history of clinically significant cardiovascular disease or electrocardiogram (EKG) findings, or medical conditions that put the patient at risk for possible cardiac side effects, 4) history of multiple adverse drug reactions, 5) current/past history of psychotic disorders or homicidality, 6) active substance use disorders (except nicotine and caffeine) within the past six months, positive urine toxicology screen, or past history of ketamine abuse, 7) requirement of excluded medications (narcotics, barbiturates, theophylline, or St. John's Wort), or 8) concurrent or recent participation in other research studies.
研究组 & 干预措施
Ketamine
Experimental
Intranasal Ketamine 50mg administered six times over three weeks.
干预措施: Ketamine (Drug)
Placebo
Placebo Comparator
Intranasal saline solution administered six times over three weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Hamilton Depression Rating Scale (HDRS)
时间窗: Up to 4 months
次要结局
未报告次要终点
研究者
Dawn F Ionescu
Assistant in Psychiatry
Massachusetts General Hospital
相似试验
Unknown
不适用
Ketamine for Treatment Resistant MDDDepressive Disorder, MajorNCT04021433Hadassah Medical Organization20
已完成
2 期
Ketamine for the Treatment of Depression in Parkinson's DiseaseDepressionParkinson's DiseaseNCT04944017Yale University51
Unknown
2 期
Emergency Ketamine Treatment of Suicidal IdeationSuicidal ImpulsesSuicidal IdeationDepressionNCT02183272University of Cincinnati60
已完成
1 期
Continuation Ketamine in Major DepressionMajor Depressive DisorderNCT00548964James Murrough36
Unknown
不适用
Long Term Follow Up KET-PDParkinson's DiseaseDepressionNCT06164756Yale University40